Recent Price Movement and Market Context
On 5 Mar 2026, Unjha Formulations Ltd’s stock price fell by 2.29% on the day, underperforming the Pharmaceuticals & Biotechnology sector by 3.39%. This decline extended a three-day losing streak during which the stock has shed 9.22% of its value. The current price of Rs.19.15 stands well below the stock’s 52-week high of Rs.30.40, representing a substantial retracement of nearly 37% from that peak.
The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bearish momentum. This contrasts with the broader market, where the Sensex opened 414.29 points higher and was trading at 79,560.49, up 0.56%. Despite the Sensex’s positive performance, led by mega-cap stocks, Unjha Formulations has not participated in the rally, highlighting its relative weakness.
Long-Term Performance and Comparative Analysis
Over the past year, Unjha Formulations Ltd has delivered a negative return of 18.25%, markedly underperforming the Sensex, which gained 7.86% during the same period. The stock’s underperformance extends beyond the last 12 months, with returns lagging the BSE500 index over one, three, and even shorter three-month intervals. This trend underscores challenges in maintaining investor confidence and market relevance.
Despite the stock’s price decline, the company’s profits have risen by 41% over the past year, resulting in a low PEG ratio of 0.1. This indicates that earnings growth has not translated into share price appreciation, possibly due to other financial or structural concerns.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Financial Health and Fundamental Metrics
Unjha Formulations Ltd’s financial profile reveals several areas of concern. The company’s long-term fundamental strength is considered weak, despite a compound annual growth rate (CAGR) of 15.77% in operating profits over the last five years. This growth rate, while positive, has not been sufficient to offset other financial pressures.
One notable weakness is the company’s ability to service its debt, reflected in a poor average EBIT to interest ratio of 0.54. This ratio indicates that earnings before interest and taxes cover interest expenses by just over half, suggesting limited cushion for debt obligations and potential vulnerability to interest rate fluctuations or credit tightening.
Additionally, the company reported flat results in the December 2025 quarter, which did not provide a catalyst for positive market sentiment. The combination of subdued recent earnings and debt servicing challenges has contributed to the stock’s diminished appeal.
Valuation and Shareholder Composition
Despite the stock’s weak price performance, certain valuation metrics remain attractive. The company boasts a return on equity (ROE) of 33.1%, which is considered very strong within the Pharmaceuticals & Biotechnology sector. Furthermore, the stock trades at a price-to-book value of 2.9, indicating a valuation discount relative to its peers’ historical averages.
The majority of the company’s shares are held by non-institutional investors, which may influence liquidity and trading dynamics. This shareholder composition can sometimes lead to increased volatility or reduced institutional support during periods of market stress.
Sector and Market Environment
The Pharmaceuticals & Biotechnology sector has experienced mixed performance recently, with some stocks benefiting from broader market rallies while others, like Unjha Formulations Ltd, have lagged. The Sensex’s current positioning below its 50-day moving average, despite trading above the 200-day moving average, suggests a cautiously optimistic market environment. However, Unjha Formulations’ consistent trading below all major moving averages highlights its divergence from sector and market trends.
Is Unjha Formulations Ltd your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Summary of Key Metrics
To summarise, Unjha Formulations Ltd’s stock has reached a new 52-week low of Rs.19.15, reflecting a sustained period of price weakness. The stock’s underperformance relative to the Sensex and its sector, combined with trading below all major moving averages, underscores the challenges faced by the company in the current market environment.
Financially, while the company has demonstrated moderate operating profit growth and a strong ROE, concerns remain regarding its debt servicing capacity and recent flat quarterly results. The valuation metrics suggest the stock is trading at a discount compared to peers, but this has not yet translated into price recovery.
Overall, the stock’s current position reflects a complex interplay of financial performance, market sentiment, and sector dynamics, as captured by its Mojo Score of 26.0 and a recent downgrade to a Strong Sell rating on 12 Jan 2026.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
